213 related articles for article (PubMed ID: 37939766)
1. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.
Zhou Z; Wang H; Li J; Jiang X; Li Z; Shen J
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127911. PubMed ID: 37939766
[TBL] [Abstract][Full Text] [Related]
2. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.
Li JH; Huang LJ; Zhou HL; Shan YM; Chen FM; Lehto VP; Xu WJ; Luo LQ; Yu HJ
Acta Pharmacol Sin; 2022 Nov; 43(11):2749-2758. PubMed ID: 35484402
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
5. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
[TBL] [Abstract][Full Text] [Related]
6. Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.
Yang J; Li Z; Shen M; Wang Y; Wang L; Li J; Yang W; Li J; Li H; Wang X; Wu Q; Gong C
Adv Sci (Weinh); 2021 Jul; 8(13):2100292. PubMed ID: 34258164
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
10. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
11. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.
Yin S; Chen Z; Chen D; Yan D
Theranostics; 2023; 13(5):1520-1544. PubMed ID: 37056572
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 and DNA Damage Response in Cancer.
Kciuk M; Kołat D; Kałuzińska-Kołat Ż; Gawrysiak M; Drozda R; Celik I; Kontek R
Cells; 2023 Feb; 12(4):. PubMed ID: 36831197
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
14. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
[TBL] [Abstract][Full Text] [Related]
15. Dual-Responsive Core-Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy.
Liu J; Li G; Guo H; Ni C; Gao Y; Cao X; Xia J; Shi X; Guo R
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12809-12821. PubMed ID: 36853989
[TBL] [Abstract][Full Text] [Related]
16. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
[TBL] [Abstract][Full Text] [Related]
17. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
18. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
[TBL] [Abstract][Full Text] [Related]
19. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
20. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
